At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 200 enrolled
Drug / intervention
edaravone dexborneoldrug
Likely dose
edaravone dexborneol 37.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Improving Neuroprotective Strategy for Ischemic Stroke With Sufficient Recanalization After Thrombectomy by Edaravone Dexborneol (INSIST-ED): a Prospective, Randomized, Double Blinded, Multi-centre Study
In Brief
A Phase 2 clinical trial evaluating edaravone dexborneol for Stroke and Endovascular Thrombectomy. Completed, enrolled 200 participants across 1 site.
Detailed Summary
To explore the safety and efficacy of edaravone dexborneol for the treatment of acute ischemic stroke patients who received endovascular thrombectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Endovascular Thrombectomy
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedDec 2020
Enrollment StartFeb 2021
Primary CompletionOct 2022
TodayJul 2026
First PostedDec 16, 2020
Enrollment StartFeb 23, 2021
Primary CompletionOct 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.5 years ago
Interventions
edaravone dexborneoldrug
Intravenous injections of edaravone dexborneol (37.5mg, dissolved in 100ml saline) twice a day for 12 ±2 days.